ArticleBMC medicine2019
Antibody responses to merozoite antigens after natural Plasmodium falciparum infection: kinetics and longevity in absence of re-exposure.
Article in BMC medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 83 citations in OpenAlex.
- Assessing the Effect of Malaria Exposure History on Tetanus Antibody Waning Rates Among Children in Jinja and Tororo Districts, Uganda.The Journal of infectious diseases · 2026Article
- Malaria exposure history shapes PD-1 expression across human B-cell subsets during acute Plasmodium falciparum infection.BMC microbiology · 2026Article
- NK cell cytotoxicity is transiently enhanced during acute malaria and modulated by the host microenvironment.JCI insight · 2026Article
- Understanding the Epidemiology of Malaria in Zanzibar Through Molecular and Serological Analysis of Samples Collected During Reactive Case Detection.Open forum infectious diseases · 2026Article
- Malaria antibody responses augment surveillance in low-transmission settings in the Upper River Region, the Gambia.Frontiers in epidemiology · 2026Article
- Article
- TLR9 gene polymorphism -1237T/C (rs5743836) is associated with low IgG antibody response against PvCSP variants in symptomatic P. vivax infections in Venezuela.PLoS neglected tropical diseases · 2025Article
- T-follicular helper cell profiles differ by malaria antigen and for children compared to adults.eLife · 2025Article
- Mathematical modeling of malaria vaccination with seasonality and immune feedback.PLoS computational biology · 2025Article
- Functionality of Toxoplasma gondii antibodies in a population of Beninese pregnant women exposed to malaria.Scientific reports · 2025Article
- Correlates of Protection Against Symptomatic COVID-19: The CORSER 5 Case-Control Study.Open forum infectious diseases · 2025Article
- Plasmodium Falciparum and mosquito vector IgG patterns across suspected malaria cases in Ghana.BMC infectious diseases · 2024Article
- Serodynamics: A primer and synthetic review of methods for epidemiological inference using serological data.Epidemics · 2024Review
- Association of the humoral immune response with the inflammatory profile in Plasmodium vivax infections in pregnant women.PLoS neglected tropical diseases · 2024Observational
- Antibodies to PfEMP1 and variant surface antigens: Protection after controlled human malaria infection in semi-immune Kenyan adults.The Journal of infection · 2024Article
- Case Report: Challenges of Diagnosing Malaria in Returning Travelers at the Height of COVID-19 Pandemic.The American journal of tropical medicine and hygiene · 2024Article
- Naturally acquired IgG responses toFrontiers in immunology · 2024Article
- Article
- High Prevalence of PolyclonalTropical medicine and infectious disease · 2023Article
- Characterization of the primary antibody response to Plasmodium falciparum antigens in infants living in a malaria-endemic area.Malaria journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 5 countries.
Funding
Abstract
backgroundAntibodies against merozoite antigens are key components of malaria immunity. The naturally acquired antibody response to these antigens is generally considered short-lived; however, the underlying mechanisms remain unclear. Prospective studies of travellers with different levels of prior exposure, returning to malaria-free countries with Plasmodium infection, offer a unique opportunity to investigate the kinetics and composition of the antibody response after natural infection.
methodsAdults diagnosed with P. falciparum malaria in Stockholm, Sweden (20 likely malaria naïve and 41 with repeated previous exposure during residency in sub-Saharan Africa) were sampled at diagnosis and 10 days and 1, 3, 6, and 12 months after treatment. Total and subclass-specific IgG responses to P. falciparum merozoite antigens (AMA-1, MSP-1
resultsA majority of individuals mounted detectable antibody responses towards P. falciparum merozoite antigens at diagnosis; however, the magnitude and breadth were greater in individuals with prior exposure. In both exposure groups, antibody levels increased rapidly for 2 weeks and decayed thereafter. Previously exposed individuals maintained two- to ninefold greater antibody levels throughout the 1-year follow-up. The half-lives of malaria-specific long-lived ASCs, responsible for maintaining circulating antibodies, ranged from 1.8 to 3.7 years for merozoite antigens and were considerably short compared to tetanus-specific ASCs. Primary infected individuals did acquire a long-lived component of the antibody response; however, the total proportion of long-lived ASCs generated in response to infection was estimated not to exceed 10%. In contrast, previously exposed individuals maintained substantially larger numbers of long-lived ASCs (10-56% of total ASCs).
conclusionThe short-lived nature of the naturally acquired antibody response, to all tested merozoite antigens, following primary malaria infection can be attributed to a combination of a poor acquisition and short half-life of long-lived ASCs. Greater longevity is acquired with repeated infections and can be explained by the maintenance of larger numbers of long-lived ASCs. These insights advance our understanding of naturally acquired malaria immunity and will guide strategies for further development of both vaccines and serological tools to monitor exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.